Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 16 of 16

List	Outcome	Time frame	Description
Primary	Change in minimal erythema dose (MED) in patients with XP-C.	From baseline to day 76.	MED is the lowest dose of UV light that causes reddening of the skin.
Primary	Change in MED in patients with XP-V.	From baseline to day 76.	MED is the lowest dose of UV light that causes reddening of the skin.
Secondary	Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-C.	From baseline to day 76.	Analysis of UV photoproducts from skin samples.
Secondary	Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-C.	From baseline to day 76.	Analysis of DNA repair mechanisms from skin samples.
Secondary	Changes in UV-induced DNA damage, as assessed by quantification of UV photoproduct levels in patients with XP-V.	From baseline to day 76.	Analysis of UV photoproducts from skin samples.
Secondary	Changes in UV-induced DNA damage repair capacity, as assessed by quantification of DNA repair mechanisms in patients with XP-V.	From baseline to day 76.	Analysis of DNA repair mechanisms from skin samples.
Secondary	Change in skin disease severity in patients with XP-C (A).	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in skin disease severity in patients with XP-V (A)	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in skin disease severity in patients with XP-C (B).	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in skin disease severity in patients with XP-V (B).	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in skin disease severity in patients with XP-C (C).	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in skin disease severity in patients with XP-V (C).	From baseline to day 76.	The higher the score, the more severe the disease.
Secondary	Change in quality of life assessed by a disease specific tool (A) in patients with XP-C.	From baseline to day 76.	Higher scores represent worse health-related quality of life.
Secondary	Change in quality of life assessed by a disease specific tool (A) in patients with XP-V.	From baseline to day 76.	Higher scores represent worse health-related quality of life.
Secondary	Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-C.	From baseline to day 76.	Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.
Secondary	Change in quality of life assessed by a validated global quality of life tool (B) in patients with XP-V.	From baseline to day 76.	Score calculated in impairment percentages, with higher numbers indicating greater impaired quality of life.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05370235/registered

API reference For AI assistants